The hemostatic system as a modulator of atherosclerosis by Paramo, J.A. (José Antonio)
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;3 nejm.org july 21, 2011278
do not observe, in an underpowered study, a pat-
tern of mutual exclusivity between NFKBIA dele-
tion and EGFR amplification when analyzing to-
gether grades II, III, and IV gliomas, nor do they 
find a relationship between survival and having 
a tumor that bears an NFKBIA deletion. Since the 
publication of our report, we have gone on to test 
these associations with the use of extended data 
from the Cancer Genome Atlas (TCGA) project. 
Using gene copy-number data generated by two 
independent TCGA Genome Characterization Cen-
ters on different genotyping platforms, we again 
observed a pattern of relative mutual exclusivity 
between deletion of NFKBIA and amplification of 
EGFR in glioblastomas (P = 2×10−3 by Pearson’s chi-
square test; odds ratio for concomitant deletion 
and amplification, 0.46; 95% confidence interval 
[CI], 0.29 to 0.74) (Fig. 1A in the Supplementary 
Appendix, available with the full text of this let-
ter at NEJM.org). We also again observed that pa-
tients with tumors with the NFKBIA deletion had 
poorer outcomes than did those who had glio-
blastomas with normal gene dosages of NFKBIA 
and EGFR (hazard ratio for death with the NFKBIA 
deletion, as compared with normal dosages of 
both NFKBIA and EGFR, 1.41; 95% CI, 1.02 to 1.94; 
P = 0.039 by the Cox model), and had outcomes 
similar to those with tumors harboring EGFR 
amplification (hazard ratio for death with iso-
lated NFKBIA deletion, as compared with isolated 
EGFR amplification, 0.93; 95% CI, 0.68 to 1.29; 
P = 0.68 by the Cox model) (Fig. 1B in the Supple-
mentary Appendix). The estimated median survival 
times were 47 weeks for patients whose tumors 
harbored an isolated NFKBIA deletion, 53 weeks for 
those whose tumors had isolated EGFR amplifi-
cation, and 67 weeks for those whose tumors had 
normal dosages of both NFKBIA and EGFR.
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The Hemostatic System as a Modulator of Atherosclerosis
To the Editor: In their review article (May 5 is-
sue),1 Borisoff et al. describe the role of hemo-
static mechanisms as potential modulators of 
atherosclerotic plaque phenotype. Although they 
describe the role of thrombin as a critical media-
tor in the processes of coagulation, inflamma-
tion, and maintenance of vessel walls and even as 
an anticoagulant molecule, they provide no infor-
mation regarding the contribution of the throm-
bin-activatable fibrinolysis inhibitor (TAFI) in these 
processes. TAFI is a procarboxypeptidase that on 
activation by thrombin or thrombin–thrombo-
modulin turns into a potent antifibrinolytic en-
zyme. TAFI acts as a molecular link between the 
processes of coagulation and fibrinolysis. Exces-
sive TAFI levels can foster thrombosis by induc-
ing a hypofibrinolytic state. In fact, plasma levels 
of TAFI are increased in patients with stroke and 
correlate with stroke severity in some studies.2-4 
In addition, TAFI significantly affected the effi-
cacy of recombinant tissue plasminogen activa-
tor and vessel recanalization in patients under-
going thrombolysis after acute ischemic stroke.5 
Because of the prominent role of thrombin in 
atherosclerosis, as stated by Borisoff et al., I be-
lieve that TAFI, a potent fibrinolytic inhibitor 
mediated by thrombin, should be included in dis-
cussions of the complex interplay between hemo-
stasis and atherosclerosis.
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The Authors Reply: We concur with Páramo that 
beyond modulating the ultimate clot size and ly-
sis, the fibrinolytic cascade proteins (including 
TAFI1) may also contribute to the pathophysiol-
ogy of cardiovascular disease. Nevertheless, the 
exact role of fibrinolysis in atherosclerosis remains 
highly controversial to date. Owing to space lim-
itations, we restricted the scope of the review and 
did not cover this topic.
Hypofibrinolysis has been proposed as a de-
terminant of cardiovascular disease in previous 
studies.2 Aside from their recognized effects on 
fibrin clot lysis, fibrinolytic proteins, including 
the enzyme plasmin, should be recognized for 
their involvement in regulating many other ac-
tions, such as the plasmin-mediated accelerated 
inflammation and degradation of matrix pro-
teins. Plasmin activates distinct matrix metallo-
proteinases (MMPs), such as MMP-3, 9, 12, and 
13,3 which have contributed to enhanced elastoly-
sis and collagenolysis, tunica media destruction, 
and aneurysm formation in atherosclerotic mice 
models.4 Furthermore, despite the atheroprotec-
tive effect of plasminogen and urokinase-type 
plasminogen activator, the loss of plasminogen 
activator inhibitor 1 in atherosclerotic mice has 
been paradoxically linked to increased plaque 
growth and extracellular matrix deposition.5 
Hence, the net effects of a fibrinolytic imbalance 
between plasminogen activators and their inhibi-
tors on atherosclerosis progression remain poorly 
understood.
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In Vivo Biomechanical Measurements of a Football Player’s  
C6 Spine Fracture
To the Editor: During an investigation of con-
cussion in American football players, we cap-
tured in vivo biomechanical data on a cervical 
spine fracture as it occurred in a male athlete 
(age, 18 years; height, 189.0 cm; weight, 79.4 kg) 
who was performing a head-down tackling ma-
neuver. The cornerback’s helmet was equipped 
with the Head Impact Telemetry System (Simbex), 
a six-accelerometer array that measures the loca-
tion and magnitude of an impact. The impact 
magnitude was quantified by measuring peak 
linear and rotational acceleration of the head 
with the use of the Gadd Severity Index (GSI) and 
Head Injury Criteria (HIC).1,2 The GSI and HIC 
are mathematically weighted measures of head 
acceleration and the duration of impact, with 
higher scores representing increased likelihood 
of injury.
After being transported to the emergency 
department, the athlete reported having pain in 
the head, neck, and lower back (severity between 
3 and 5 on a scale of 0 through 10, with 0 indi-
cating no pain and 10 indicating most severe 
pain) and losing consciousness for less than 10 
seconds at the time of injury. A computed tomo-
graphic (CT) scan of the brain was normal, but 
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